Phase Ib Study of Glasdegib, a Hedgehog Pathway Inhibitor, in Combination with Standard Chemotherapy in Patients with AML or High-Risk MDS.

doi:10.1158/1078-0432.CCR-17-2824

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Community

Back to search

Article

Phase Ib Study of Glasdegib, a Hedgehog Pathway Inhibitor, in Combination with Standard Chemotherapy in Patients with AML or High-Risk MDS.

Clinical cancer research : an official journal of the American Association for Cancer Research - 15 May 2018

Savona Michael R, Pollyea Daniel A, Stock Wendy, Oehler Vivian G, Schroeder Mark A, Lancet Jeffrey, McCloskey James, Kantarjian Hagop M, Ma Weidong Wendy, Shaik M Naveed, Laird A Douglas, Zeremski Mirjana, O'Connell Ashleigh, Chan Geoffrey, Cortes Jorge E

Abstract excerpt

Purpose: This open-label, multicenter, dose-finding, phase Ib study (NCT01546038) evaluated the safety, pharmacokinetics, pharmacodynamics, and clinical activity of the novel Hedgehog pathway Smoothened inhibitor glasdegib (PF-04449913) in patients (N = 52) with acute myeloid leukemia (AML) or high-risk myelodysplastic syndrome (MDS).Experimental Design: Glasdegib 100 or 200 mg was administered orally, once daily...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Antineoplastic Combined Chemotherapy Protocols

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Benzimidazoles

Share to Biomarkers

Share to Hedgehog Proteins

Share to Leukemia, Myeloid, Acute

Share to Myelodysplastic Syndromes

Share to Phenylurea Compounds

Share to Treatment Outcome

Source

Open in PubMed

Identifiers

PMID: 29463550
DOI: 10.1158/1078-0432.CCR-17-2824

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-08.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Phase Ib Study of Glasdegib, a Hedgehog Pathway Inhibitor, in Combination with Standard Chemotherapy in Patients with AML or High-Risk MDS.PMID 29463550Read ↗

Phase I combination trial of lenalidomide and azacitidine in patients with higher-risk myelodysplastic syndromes.Semantic proximity Read ↗

Efficacy evaluation of glasedgib Sonic Hedgehog pathway inhibition with or without inotuzumab in B-ALL cells using a new co-culturing system model and a validated chemosensitivity assaySemantic proximity Read ↗

The Hedgehog pathway as targetable vulnerability with 5-azacytidine in myelodysplastic syndrome and acute myeloid leukemiaSemantic proximity Read ↗

Recent advances in the design of Hedgehog pathway inhibitors for the treatment of malignanciesSemantic proximity Read ↗

Inhibition of the hedgehog pathway in advanced basal-cell carcinoma.Semantic proximity Read ↗

Phase II study of the histone deacetylase inhibitor panobinostat (LBH589) in patients with low or intermediate‐1 risk myelodysplastic syndromeSemantic proximity Read ↗

Beyond cyclopamine: Targeting Hedgehog signaling for cancer interventionSemantic proximity Read ↗

Targeting hedgehog signaling in myelofibrosis and other hematologic malignanciesSemantic proximity Read ↗

Hedgehog pathway as a drug target: Smoothened inhibitors in developmentSemantic proximity Read ↗

Final results of a phase 2, open-label study of indisulam, idarubicin, and cytarabine in patients with relapsed or refractory acute myeloid leukemia and high-risk myelodysplastic syndrome.Semantic proximity Read ↗

Design of Hedgehog pathway inhibitors for cancer treatmentSemantic proximity Read ↗

Sulforaphane promotes natural killer cell-mediated anti-tumor immune responses partially via cGAS-STING pathway in classical Hodgkin lymphomaSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.